Emerging Lipoprotein(a)-Lowering Therapies: A Meta-Analysis of Randomized Phase 2 Trials

Introduction/Background: Elevated lipoprotein(a) (Lp(a)) is a genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis, yet no approved pharmacologic therapy specifically targets Lp(a). Several RNA- and assembly-targeting agents have completed randomized dose-ranging trials. Research Question/Hypothesis: We hypothesized that emerging Lp(a)-lowering therapies produce large placebo-adjusted reductions in Lp(a) without an early serious safety signal. Methods/Approach: PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were searched through June 2026 for randomized placebo-controlled trials of investigational Lp(a)-lowering therapies in adults with elevated Lp(a). The primary efficacy outcome was placebo-adjusted percent change in Lp(a). For each trial, the most potent prespecified regimen with extractable 95% confidence intervals was pooled using inverse-variance random-effects meta-analysis. Serious adverse events were pooled as risk ratios. Results/Data: Five phase 2 randomized trials including 1,298 participants evaluated pelacarsen, olpasiran, zerlasiran, muvalaplin, and lepodisiran. Pelacarsen was summarized qualitatively because extractable comparative confidence intervals were unavailable; 20 mg weekly reduced Lp(a) by 80% versus 6% with placebo. Four trials were quantitatively pooled. Selected regimens were olpasiran 225 mg every 12 weeks, zerlasiran 450 mg every 24 weeks, muvalaplin 240 mg daily, and lepodisiran 400 mg. Trial-level placebo-adjusted Lp(a) reductions were -101.1, -85.6, -85.8, and -93.9 percentage points, respectively. Random-effects pooling showed a 91.6 percentage-point greater Lp(a) reduction versus placebo (95% CI, 85.6-97.5; I2=94.3%; Q=52.8; P-heterogeneity<0.001). RNA-targeting therapies alone showed a 93.7 percentage-point reduction (95% CI, 87.1-100.2; I2=89.3%). Serious adverse events were not significantly increased (RR, 1.09; 95% CI, 0.64-1.88; I2=0%; P=0.75). Conclusion(s): Emerging Lp(a)-lowering therapies produce profound short-term biomarker reductions, particularly RNA-targeting agents, without a pooled serious safety signal. Heterogeneity reflects different mechanisms, doses, assays, and timepoints. Completed trials remain biomarker-driven and underpowered for cardiovascular events; phase 3 outcomes data are required before clinical adoption.